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Abstract The epidemiology of systemic vasculitides
differs between Japan, Europe and North America. Taka-
yasu’s arteritis occurs frequently in Japan, unlike giant cell
arteritis. A collaborative international study comparing the
epidemiology of anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis between Japan and the
United Kingdom (UK) demonstrated that microscopic
polyangiitis and myeloperoxidase-ANCA were more
common in Japan whereas granulomatosis with polyangi-
itis and pronase 3-ANCA were more common in the UK.
These differences may be attributed to differences in lati-
tude and genetic backgounds. These findings provide use-
ful information on the aetiology and pathogenesis of
primary systemic vasculitides in various geographical
regions.
Keywords Microscopic polyangiitis  Granulomatosis
with polyangiitis  Takayasu’s arteritis  Giant cell arteritis 
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Introduction
The incidence and clinical features of several types of
vasculitides differ between Japan, Europe and North
America, unlike those of rheumatoid arthritis, systemic
lupus erythematosus, and other rheumatic diseases in these
geographical regions [1, 2]. These vasculitides are more
rare and heterogeneous in terms of clinical features, types
of anti-neutrophil cytoplasmic antibody (ANCA) and
response to treatment. Because geographical differences in
the incidence of ANCA-associated vasculitis (AAV) have
been demonstrated in Europe [3], we extended our research
to determine the incidence, clinical phenotype and the
associated genetic factors of vasculitides between Japan,
Europe, and North America. In this review, we present a
brief account of the results of these studies.
Takayasu’s arteritis (TAK) and giant cell arteritis
(GCA)
TAK and GCA are two types of vasculitis characterized by
inflammation of the large vessels.
Histologically, both demonstrate granulomatous vascu-
litis with giant cells. Fewer patients with GCA have been
reported in the Japanese literature than in the European and
North American literatures. In contrast, more patients with
TAK have been reported in Japan than in Europe or the
USA [4]. The point prevalence of GCA in Japan was 690
patients in 1997 (95 % confidence interval [CI] 400–980)
[5]. The prevalence of patients C50 years of age was 1.47
cases (95 % CI 0.86–2.10) per 10 million people in Japan
compared with 200 and 60 cases per 10 million people in
the USA and Spain, respectively [6, 7].
The reason for the low incidence of GCA in Japan
remains unclear; however, genetic factors affecting the
incidence of these diseases are unique and important. The
HLA-DRB1*0401 and HLA-DRB1*0404 haplotypes are
predominantly (60 %) detected in patients with GCA in
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America. These haplotypes were less frequently detected in
493 Japanese healthy controls (2.9 and 0.7 %, respectively)
than in 60 American healthy controls (15.9 and 3.2 %,
respectively) [5]. This explains why the incidence and/or
prevalence of GCA is not high in Japan. Moreover, our
study found no significant differences in the clinical fea-
tures of GCA between Japan and other countries, although
GCA cases are less common in Japan than in the USA or
Europe [8].
TAK, which predominantly affects young females in
Japan, affects the aortic arch (Type I), as determined by
angiography. The incidence of HLA-B52 (56 %) and
HLA-B39 (17 %) was significantly higher in patients with
TAK than in healthy controls (25 and 6 %, respectively) in
a Japanese study. However, several patients with TAK in
India and other East Asian countries are reportedly middle-
aged males who express HLA-B39 and exhibit abdominal
aorta involvement (Type III).
ANCA-associated vasculitis (AAV)
Geographic factors: the latitude of Japan
Japan is located between the latitudes of 26–45N.
Asahikawa city (43.5N) on Hokkaido Island is close to the
latitude of Lugo, Spain (42N) [1]. On this island, there are
more patients with microscopic polyangiitis (MPA); a
higher number of patients with AAV are MPO-ANCA-
positive than granulomatosis with polyangiitis (GPA)- or
pronase 3 (PR3)-positive [1]. These data are compatible
with the latitude theory of AAV [3] (Fig. 1).
On the other hand, it is interesting to note that a study
from Beijing (39.5N), China, demonstrated that 60.7 %
(54/89) of patients with GPA were MPO-ANCA-positive
and 38.2 % (34/89) were PR3-ANCA-positive. Patients
with MPO-ANCA had multiorgan involvement with higher
serum creatinine levels than PR3-ANCA-positive patients
with GPA [9].
Differences in clinical phenotypes
Differences in renal involvement in GPA and MPA
between patients in the UK and Japan were reported by
Watts et al. [10]. Supporting data indicated that patients
with localized GPA were more frequent than GPA
patients with renal involvement in Japan, which was
reported by Harabuchi et al. from Asahikawa Medical
University and confirmed in our investigation [11].
Another report by certain otolaryngologists reached the
same conclusion [12]. Moreover, two studies demon-
strated renal involvement in 12–40 % of 21 patients with
GPA [13, 14]. In another hospital-based, nationwide,
retrospective study conducted in Japan from 1988 to 1998
by the Japanese Ministry of Health, Labour and Welfare,
renal involvement was diagnosed in 39–63 % of 172
patients. In two studies by Gross et al. in Germany and
Hoffman et al. in the USA, renal involvement was diag-
nosed in 77 % of 155 patients and 77 % of 70 patients
with GPA, respectively [15, 16].
Genetic factors
A genetic analysis of patients with MPA was initiated in
1997 by the Research Committee of Intractable Vasculitis
of the Japanese Ministry of Health and Welfare (Chief
Investigator Prof. Hiroshi Hashimoto). A significant asso-
ciation between HLA-DRB1*0901 and MPA (P = 0.037;
odds ratio [OR] 2.44; 95 % CI 1.33–4.46) as well as MPO-
ANCA positivity (P = 0.014; OR 2.44; 95 % CI
1.41–4.22) was demonstrated by Tsuchiya et al. [17, 18].
Another report published in 1996 demonstrated an associ-
ation between HLA-DR9 in 62.5 % patients and cANCA-
positive GPA (10/16) compared with 26 % in healthy
controls (P \ 0.05) [19]. The decreased activation poten-
tial of natural killer cells and/or T cells associated with
killer cell immunoglobulin-like receptor or HLA genotypes
was demonstrated in patients with MPA, thus suggesting
that these patients may have insufficient resistance to
infections. An autoreactive T-cell response to the MPO
fragments was detected in addition to the distinct epitopes
of MPO fragments recognized by HLA-DR-restricted
CD4 ? T cells [20].
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Fig. 1 Geographical differences in the incidences of vasculitides.
GCA and GPA occur more frequently in North Europe and North
America whereas Takayasu arteritis and MPA occur more frequently
in Japan
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The Miyazaki-UK Study: a population-based,
prospective study
The epidemiological manifestations of AAV differ between
geographical regions [3]. However, there are no prospective
studies comparing the incidence of AAV between Japan and
Europe over the same time period using similar case defini-
tions [10, 21]. The incidence of AAV in Miyazaki Prefecture,
Japan, and Norfolk, UK, between 2005 and 2009, was pro-
spectively determined using a population-based method.
Patients with AAV were defined and classified according to
the European Medicines Agency algorithm. The number of
cases of AAV in Japan and the UK was 86 and 50, respec-
tively, and the average annual incidence over the 5-year period
was 22.6 per million people (95 % CI 19.1–26.2) and 21.8 per
million people (95 % CI 12.6–30.9) in Japan and the UK,
respectively. The average patient age was higher in Japan than
the UK (mean [median]) 69.7 [72] vs 60.5 [61] years]. MPA
was the predominant subtype in Japan (83 %), whereas GPA
was more frequent in the UK (66 %). Regarding the pattern of
ANCA positivity, [80 % patients in Japan were pANCA-
and/or MPO-positive, whereas two-thirds of patients in the
UK were cANCA- and/or PR3-positive. Renal involvement
in patients with MPA was common in both countries but it
was significantly less common in GPA patients in Japan than
in GPA patients in the UK. There was no major difference in
the incidence of AAV between Japan and the UK, but this
prospective study found that MPA and MPO-ANCA were
more common in Japan whereas GPA and PR3-ANCA were
more common in the UK [21].
Conclusion
These findings provide useful information on the aetiology
and pathogenesis [22, 23] of primary systemic vasculitides
in various geographical regions.
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